Lexaria animal study interim results: DehydraTECH liraglutide and CBD show weight loss; CFO Cabatuan resigns

Lexaria Bioscience Corp.

CFO Nelson Cabatuan resigned effective July 15; becomes Chief Strategic Financial Advisor; 150k unvested options expire, vested 50k options reduced to July 2026.
In study WEIGHT-A24-1, DehydraTECH-CBD3 and DehydraTECH-liraglutide showed largest weight loss: -1.50% and -1.58% over 28 days.
DehydraTECH works with semaglutide both with and without SNAC; pure semaglutide arm performed similarly to reformulated Rybelsus.
Dosing in final four study arms (Cohort 2) began, combining DehydraTECH-semaglutide+CBD and DehydraTECH-liraglutide+CBD; results expected mid-October.
Study is exploratory; not powered for statistical significance; blood glucose and PK data pending.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Nelson Cabatuan

Chief Financial Officer

LEXX · Lexaria Bioscience Corp.

Effective: 2024-07-15
Filed: July 17, 2024, 7:59 PM ET

Effective on July 15, 2024, Mr. Nelson Cabatuan resigned from his position as the Company’s Chief Financial Officer in order to focus his attention on corporate finance and strategic industry relationships for Lexaria as its Chief Strategic Financial Advisor.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Nelson Cabatuan resigned as Chief Financial Officer at Lexaria Bioscience Corp..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Effective on July 15, 2024, Mr. Nelson Cabatuan resigned from his position as the Company’s Chief Financial Officer in order to focus his attention on corporate finance and strategic industry relationships for Lexaria as its Chief Strategic Financial Advisor.

View on SEC.gov

Lexaria Bioscience Corp. filing history →

Source: SEC EDGAR

accession 0001640334-24-001132

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.